BridgeMD
Tests treatment safety and results for Psychotic Disorders
Official title Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders
ClinicalTrials.gov ID: NCT07455929
What this study is testing
- What it's testing
- A three-arm pilot rater-blinded randomized controlled trial is conducted, comprising Yoga-based Group Intervention (YoGI + TAU) as the experimental condition, a strength and flexibility training (SFT + TAU) group, and treatment as usual (TAU). Participants in all conditions receive the respective intervention in addition to treatment as usual (TAU) in outpatient settings in Germany.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Diagnosis of Schizophrenia Spectrum Disorder by previous (medical) reports according to ICD-10/ DSM-V
- Treated as psychiatric outpatients
- Age between 18 and 65 years
- Ability to give informed consent
- Willingness and ability to engage in psychotherapeutic group therapy
You likely can't join if
- Neurological disorders and history of severe traumatic brain injury in the past that may affect cognitive functioning
- Acute substance dependence, excluding nicotine and prescribed medication
- PANSS-P score on one item \> 6 (= very severe)
- Ineligibility for group participation
- Acute suicidality, indicated by a score \> 1 on item 8 of the Calgary Depression Scale for Schizophrenia (Addington, Addington, Maticka-Tyndale, \&...
- Conflicting co-therapy such as electroconvulsive therapy or ketamine treatment as well as intensive psychotherapy
See the full eligibility criteria
- Diagnosis of Schizophrenia Spectrum Disorder by previous (medical) reports according to ICD-10/ DSM-V
- Treated as psychiatric outpatients
- Age between 18 and 65 years
- Ability to give informed consent
- Willingness and ability to engage in psychotherapeutic group therapy
- Low to moderate psychotic state indicated with a score of ≤ 6 for each item at the Positive scale of the Positive and Negative Syndrome Scale (PANSS, Peralta \& Cuesta, 1994)
- Neurological disorders and history of severe traumatic brain injury in the past that may affect cognitive functioning
- Acute substance dependence, excluding nicotine and prescribed medication
- PANSS-P score on one item \> 6 (= very severe)
- Ineligibility for group participation
- Acute suicidality, indicated by a score \> 1 on item 8 of the Calgary Depression Scale for Schizophrenia (Addington, Addington, Maticka-Tyndale, \& Joyce, 1992)
- Conflicting co-therapy such as electroconvulsive therapy or ketamine treatment as well as intensive psychotherapy
The study team makes the final eligibility decision.
Where it's taking place
- Berlin, Germany
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Berlin, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.